Live Feeds
● LIVE Updated 1h ago · 8 sources tracked

BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth

Bristol Myers Squibb's lung disease and solid tumor drugs have shown positive results in late-stage trials, offering hope for post-patent cliff growth. The company's lung disease drug succeeded at a lower dose, while a solid tumor drug also showed promise. This development could help BMS offset patent expirations and boost its pipeline.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial
  • ✓ BMS scores pivotal trial win for lower dose of admilparant in IPF
  • ✓ Bristol Myers' drugs succeed in treating lung disease, cancer
🛡️ Source Corroboration: 8 independent reporting domains (85% confidence) ⏱ Read time: ~2 min

What changed

BMS reported positive Phase 3 trial results for its lung disease and solid tumor drugs, with the lung disease drug succeeding at a lower dose.

Live updates

  1. BMS lung disease, solid tumor drugs show promise

    Bristol Myers Squibb's lung disease and solid tumor drugs have shown positive results in late-stage trials, offering hope for post-patent cliff growth. The company's lung disease drug succeeded at a lower dose, while a solid tumor drug also showed promise. This development could help BMS offset patent expirations and boost its pipeline.

    Why it matters

    BMS is facing a patent cliff, with several key patents set to expire soon. The company is under pressure to deliver new growth drivers. The positive trial results could help BMS maintain its market position and provide new revenue streams.

    What is confirmed

    • Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial
    • BMS scores pivotal trial win for lower dose of admilparant in IPF
    • Bristol Myers' drugs succeed in treating lung disease, cancer

    Still unconfirmed

    • Contineum Therapeutics shares surge 27% after Bristol Myers Squibb reports positive Phase 3 trial results

    What to watch next

    • BMS regulatory approval for lung disease and solid tumor drugs
    • BMS commercial launch of lung disease and solid tumor drugs
    • Impact of BMS drugs on market position and revenue growth
    Sources used for this update (8)
    1. Fierce Biotech — BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
    2. Reuters — Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial
    3. Yahoo Finance — Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results
    4. Bloomberg.com — Bristol Myers’ Drugs Succeed in Treating Lung Disease, Cancer
    5. Investor's Business Daily — Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival Crashes
    6. BioSpace — BMS’ Phase 3 win for lung drug clouded by high-dose miss
    7. FirstWord Pharma — BMS scores pivotal trial win for lower dose of admilparant in IPF
    8. BioPharma Dive — Bristol Myers dips on ‘confounding’ lung drug results
    confidence 85%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community